A potent veterinary tranquilizer is rapidly infiltrating New York’s illicit opioid supply, leading to a sharp increase in overdose deaths and complicating emergency medical responses. New peer-reviewed research from state and New York City health officials reveals that medetomidine is now a common hidden ingredient in street drugs.
A Rapid Market Shift
Between May and December 2024, medetomidine was detected in approximately one out of every four opioid samples tested at community drug-checking sites. The prevalence peaked in May, appearing in more than 44% of tested samples.
The human cost of this trend is evident in preliminary death certificate data from New York City. Medetomidine was identified as a contributing factor in 134 overdose deaths last year, a significant jump from 18 deaths the previous year.
Medical Complications and Risks
Medetomidine is not an opioid; it is a sedative in the same family as xylazine, often referred to as “tranq.” It is almost always found mixed with fentanyl, and occasionally alongside xylazine.
This combination creates a dangerous scenario for first responders because medetomidine does not respond to naloxone, the standard medication used to reverse opioid overdoses. Dr. David Holtgrave, a co-author of the study and adviser to the state Department of Health commissioner, notes that bystanders should still administer naloxone because fentanyl is typically present.
Patients arriving at hospitals often exhibit deep sedation, shaking, and very low blood pressure. This represents frequently followed by severe withdrawal symptoms, including uncontrollable vomiting, heavy sweating, and racing heart rates.
State Response and Future Monitoring
State and city officials first identified the drug in May 2024 via an upstate sample sold as heroin. Since then, routine testing has shown medetomidine levels remaining around 30% of opioid samples.
While some of the rise in reported deaths could reflect expanded testing, Dr. Holtgrave suggests the persistence of the drug indicates a genuine market shift. Public alerts have been issued to clinicians, harm reduction groups, and drug users.
Looking forward, officials may attempt to identify unknown substances earlier by utilizing a public drug-checking dashboard. The state is likely to add new adulterants to this tracking system as tips arrive from laboratories and users.
Frequently Asked Questions
What is medetomidine?
Medetomidine is a veterinary tranquilizer and a non-opioid sedative. It belongs to the same family of sedatives as xylazine and is frequently found mixed with fentanyl in the illicit drug supply.
Why is naloxone less effective in these overdoses?
Naloxone is designed to reverse opioid overdoses, but because medetomidine is not an opioid, it does not respond to the medication. However, responders are still advised to use it because fentanyl is usually present in the mixture.
How has the death toll changed in New York City?
According to preliminary death certificate data, medetomidine-linked overdose deaths in New York City rose from 18 in 2024 to 134 in 2025.
How can public health systems better prepare for the sudden appearance of unknown chemical adulterants in the drug supply?